Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome
- 26 October 2021
- journal article
- case report
- Published by Springer Nature in International Journal of Hematology
- Vol. 115 (4) , 585-589
Abstract
A 53-year-old woman was diagnosed with lymphoplasmacytic lymphoma (LPL)/Waldenström's macroglobulinemia (WM) in 2008. Six courses of R-COP (rituximab, cyclophosphamide, vincristine, and prednisolone) resulted in complete remission, but LPL/WM relapsed in 2015. After six courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), the M-peak disappeared, but the patient presented with muscle weakness and sensory disturbance in the lower extremities. No lesions were apparent in the brain parenchyma, but T2-weighted magnetic resonance imaging (MRI) showed a signal-hyperintense area with contrast enhancement in the spinal cord at the C2–4 and Th2–3 levels, and cerebrospinal fluid (CSF) examination showed only a few mononuclear cells. In 2020, the patient started to require walking assistance, and MRI findings worsened. Neurologically, lower limb muscle strength was reduced (manual muscle test score 3), and sensations of touch and pain were about 30% of normal. Vibratory sensation was absent at the knees and medial malleoli, accompanied by dysuria due to neurogenic bladder. CSF cell count was 15/μl (all mononuclear cells). Bing–Neel syndrome (BNS) was diagnosed and tirabrutinib was started. Within 2 months of treatment, lower extremity muscle strength had normalized and MRI findings had improved. Tirabrutinib may offer a promising therapeutic option for BNS.Keywords
This publication has 22 references indexed in Scilit:
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemiaBlood, 2016
- Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signalingLeukemia, 2016
- Efficacy of ibrutinib in the treatment of Bing–Neel syndromeAmerican Journal of Hematology, 2015
- Central nervous system involvement by Waldenström macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective studyBritish Journal of Haematology, 2015
- Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapseBlood, 2015
- Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).Haematologica, 2015
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaNew England Journal of Medicine, 2015
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaBlood, 2013
- Bing–Neel syndrome: an illustrative case and a comprehensive review of the published literatureJournal of Neuro-Oncology, 2009